|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
Datamonitor, March 2010, Pages: 279
Introduction
The five tumor types covered in this report are set to account for nearly 898,000 new patients in 2010. Collectively, the 18 drugs in Phase III development for the gastrointestinal cancers are forecast to achieve $5,404m in sales by 2019. Not all unmet needs will be fulfilled, therefore significant commercial opportunities exist for drug developers seeking to enter the market.
Scope
-Examination of the gastrointestinal cancers pipeline with in-depth clinical and commercial profiles of Phase III candidates
-Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions
-Segmentation and analysis of the current gastrointestinal cancers pipeline by developmental phase, drug class and company
-Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
Highlights
There are 166 drugs in clinical development for the gastrointestinal cancers. Molecular targeted therapies are the predominant therapy class in the pipeline, accounting for 67%. Cytotoxic therapies account for 2% of the pipeline, while immunotherapies account for 15% and gene therapies for 16%.
Colorectal cancer is one of the 'big four' tumor types and has traditionally been a popular R&D target due to its high patient and commercial potential. Following the success of Avastin, drug developers are trying to emulate this, with all three late-phase pipeline products for colorectal cancer targeting angiogenesis.
Pancreatic cancer suffers from high levels of unmet need due to poor prognosis and a resistant nature, resulting in a high rate of Phase III failure. High unmet needs are likely to equate to high commercial reward, which has been noticed by drug developers, making pancreatic cancer the second most popular R&D target after colorectal cancer.
Reasons to Purchase
-Identify key drugs and companies within the gastrointestinal cancers pipeline based on sales forecasts to 2019 and Datamonitor drug assessment
-Characterize unmet need and poorly served patient groups within gastrointestinal cancer and assess the potential for pipeline products to fulfill them
-Assess the shifting gastrointestinal cancer market dynamic and how future treatment will incorporate pipeline products
Customers who bought this item also bought
Gastric Cancer Drug Discoveries: What the Future Holds
Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress
Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth
Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine
Pipeline Insight: Lung Cancers Overview - Intensive R&D activity but little improvement in patient outcomes
Global Biopharma Outlook 2012 - Major US and EU Pharma
Stakeholder Opinions: Hepatocellular cancer
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Drug Delivery in Cancer - Technologies, Markets and Companies
|
|
|
|
